ArticleJournal of leukocyte biology2026
An optimized method to differentiate HL60 cells into neutrophil-like cells.
Article in Journal of leukocyte biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nuclear remodeling and optimal migration emerge early, and constriction-passage progressively improves during hematopoietic stem cells to neutrophils differentiation.bioRxiv : the preprint server for biology · 2026Article
- Development of flow cytometry bead-based opsonophagocytic assays to dissect cell-mediated functional antibody responses to malaria vaccines.Malaria journal · 2026Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
The HL60 promyelocytic leukemia cell line is widely used to investigate neutrophil biology due to its genetic tractability and accessibility. HL60 cells can be differentiated into neutrophil-like cells using all-trans retinoic acid (ATRA) or dimethyl sulfoxide (DMSO) treatment. However, these approaches produce cells that lack critical features of mature granulocytes, such as robust chemotaxis with ATRA treatment or multilobed nuclear morphology with DMSO treatment. To overcome these limitations, we developed a sequential differentiation protocol-ATRA for 1 d followed by DMSO for 4 d (A1D4)-which yields neutrophil-like cells that more faithfully recapitulate the morphology and functionality of mature human neutrophils. A1D4-differentiated HL60 cells display segmented nuclei with low lamin A/C expression and demonstrate strong chemotactic, oxidative burst, and phagocytic activity. This protocol combines the advantages of treatment with the individual compounds, producing cells that closely mimic primary human neutrophils in both phenotype and function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.